Drug Profile
Nemtabrutinib - Merck and Co
Alternative Names: ARQ-531; MK-1026Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator ArQule
- Developer Merck & Co
- Class Antineoplastics; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic lymphocytic leukaemia
- Phase II B-cell lymphoma; Follicular lymphoma; Haematological malignancies
- No development reported Richter's syndrome
Most Recent Events
- 13 Dec 2023 Phase-III clinical trials in Chronic lymphocytic leukaemia (First-line therapy) in Israel, USA (PO) (NCT06136559)
- 13 Dec 2023 Merck Sharp & Dohme initiates enrolment in a phase III BELLWAVE-011 trial for Chronic lymphatic leukaemia (First-line therapy) in Taiwan (NCT06136559)
- 18 Nov 2023 Merck Sharp & Dohme plans a phase III BELLWAVE-011 trial for Chronic lymphocytic leukemia (First-line therapy) in December 2023 (NCT06136559; EudraCT-2022-501697-19)